M. Small

发表

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

L. Gumbrell, V. Harvey, B. Baguley, 2003, British Journal of Cancer.

Effect of ONO‐5334 on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Osteoporosis: 2‐Year Results From the OCEAN Study

T. Spector, S. Boonen, R. Eastell, 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Safety and efficacy of the cathepsin K inhibitor ONO‐5334 in postmenopausal osteoporosis: The OCEAN study

T. Spector, S. Boonen, R. Eastell, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Sexual Functioning in Long-Term Breast Cancer Survivors Treated with Adjuvant Chemotherapy

P. Jacobsen, C. Cox, M. Small, 2002, Breast Cancer Research and Treatment.

Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome.

P. Abrams, P. Radziszewski, C. Chapple, 2014, The Journal of urology.

Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial

R. Eastell, H. Yamada, M. Small, 2015, Osteoporosis International.

Pharmacodynamic Effects on Biochemical Markers of Bone Turnover and Pharmacokinetics of the Cathepsin K Inhibitor, ONO‐5334, in an Ascending Multiple‐Dose, Phase 1 Study

Yoshitaka Hashimoto, M. Small, Shinichi Nagase, 2012, Journal of clinical pharmacology.

Modeling and simulation of bone mineral density response from a phase 2 study of ONO‐5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis

I. Ieiri, H. Kastrissios, J. Monteleone, 2014, Journal of clinical pharmacology.

The Effect of the Cathepsin K Inhibitor ONO‐5334 on Trabecular and Cortical Bone in Postmenopausal Osteoporosis: The OCEAN Study

H. Genant, R. Eastell, T. Fuerst, 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO‐5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females

I. Ieiri, Chihiro Hasegawa, T. Ohno, 2014, Journal of clinical pharmacology.

Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women

Yoshitaka Hashimoto, M. Small, Shinichi Nagase, 2013, Journal of Bone and Mineral Metabolism.

Efficacy and safety of the cathepsin K inhibitor, ONO-5334, and alendronate on post-menopausal osteopenia or osteoporosis: 2-year results from the ocean study

T. Spector, S. Boonen, R. Eastell, 2011 .

Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women.

Yoshitaka Hashimoto, M. Small, Shinichi Nagase, 2012, British journal of clinical pharmacology.

Effect of escalating doses of recombinant human granulocyte colony-stimulating factor (filgrastim) on circulating neutrophils in healthy subjects.

J. Borleffs, M. Small, J. Van Strijp, 1998, Clinical therapeutics.

Oral pefloxacin mesylate in the treatment of continuous ambulatory peritoneal dialysis associated peritonitis: an open non-comparative study.

M. Small, R. Ellis-Pegler, J. Collins, 1990, Journal of Antimicrobial Chemotherapy.